Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN 7.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs AMINOSYN 7%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Aminosyn 7% provides a mixture of essential and nonessential amino acids, serving as substrates for protein synthesis, thereby supporting nitrogen balance and tissue repair. It acts as a source of caloric nitrogen in parenteral nutrition.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous: 500 mL to 2 L of 7% solution (35-140 g amino acids) per day by central or peripheral infusion, adjusted based on metabolic needs and nitrogen balance, usually infused at a rate not exceeding 0.1 g/kg/hour.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Not applicable as a single entity; amino acids are utilized rapidly for protein synthesis and energy. Plasma amino acid levels decline with a terminal half-life of approximately 10-20 minutes post-infusion, reflecting rapid tissue uptake.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Primarily renal elimination of infused amino acids as metabolic byproducts (urea, ammonia) and a small fraction of unchanged amino acids. Renal excretion accounts for >90% of elimination; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution